Asaad AZARNEZHAD, Mina TABRIZI, Firouzeh JAVAN, Parvin MEHDIPOUR

Detection of CCND1, C-MYC, and FGFR1 amplification using modified SYBR Green qPCR and FISH in breast cancer

Background/aim: The aims of this study were to detect CCND1, C-MYC, and FGFR1 amplification using qPCR, confirmation withFISH, and to further assess their clinicopathological relevance.Materials and methods: Thirty-five breast tumor samples were analyzed for amplification of the selected genes using modified SYBRGreen qPCR. The accuracy of the qPCR was assessed by FISH as a gold-standard method.Results: CCND1, C-MYC, and FGFR1 amplifications were observed in 34.28%, 28.57%, and 17.14% of the 35 samples, respectively.qPCR results were significantly confirmed by FISH and qPCR and FISH showed excellent correlation (P = 0.000). CCND1 amplificationwith tumor stage (P = 0.044), positive metastatic status (P = 0.042), positive family history (P = 0.042), and C-MYC status (P = 0.005);C-MYC amplification with tumor size (P = 0.021), tumor grade (P = 0.018), tumor stage (P = 0.032), and FGFR1 status (P < 0.000); andFGFR1 amplification with tumor size (P = 0.041) and positive ER status (P = 0.042) were statistically associated.Conclusion: Our findings revealed that the applied qPCR approach could precisely quantify the relative gene copy number. Morestudies with a larger sample size are suggested to confirm the clinicopathological value of CCND1, C-MYC, and FGFR1 amplification.

PDF

___

Albertson DG. Gene amplification in cancer. Trends Genet 2006; 22: 447-455.
Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D. Integrated profiling of basal and luminal breast cancers. Cancer Res 2007; 67: 11565-11575.
Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V, Dezso Z, Mulvey L, Macconaill LE, Winckler W. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res 2008; 68: 9532-9540.
Bieche I, Olivi M, Nogues C, Vidaud M, Lidereau R. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 2002; 86: 580.
Reis-Filho JS, Savage K, Lambros MB, James M, Steele D, Jones RL, Dowsett M. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006; 19: 999.
Jang MH, Kim EJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Kim IA, Park SY. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res 2012; 14: R115.
Elsheikh SE, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, Ellis IO, Reis-Filho JS. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007; 9: R23.
Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene 2003; 22: 6497-6507.
Strachan T, Read A. Human Molecular Genetics. New York, NY, USA: Garland Science; 2010.
Hömig-Hölzel C, Savola S. Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics. Diagn Mol Pathol 2012; 21: 189-206.
D’haene B, Vandesompele J, Hellemans J. Accurate and objective copy number profiling using real-time quantitative PCR. Methods 2010; 50: 262-270.
Soltany-Rezaee-Rad M, Sepehrizadeh Z, Mottaghi-Dastjerdi N, Yazdi MT, Seyatesh N. Comparison of SYBR Green and TaqMan real-time PCR methods for quantitative detection of residual CHO host-cell DNA in biopharmaceuticals. Biologicals 2015; 43: 130-135.
Frank SG, Bernard PS. Profiling breast cancer using real-time quantitative PCR. In: Wittwer C, Hahn M, Kaul K, editors. Rapid Cycle Real-Time PCR—Methods and Applications. Berlin, Germany: Springer; 2004. pp. 95-106.
Ohshima K, Hatakeyama K, Nagashima T, Watanabe Y, Kanto K, Doi Y, Ide T, Shimoda Y, Tanabe T, Ohnami S. Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors. Sci Rep 2017; 7: 1.
Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Köchli O. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004; 64: 8534- 8540.
Petrov A, Pavlenko I, Gorelik M. Gene amplification and coamplification in breast cancer: frequency and prognosis value. Arkh Patol 2012; 75: 54-57.
Murthy SK, Magliocco AM, Demetrick DJ. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIα genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization. Arch Pathol Lab Med 2005; 129: 39-46.
Olsson H, Jansson A, Holmlund B, Gunnarsson C. Methods for evaluating HER2 status in breast cancer: comparison of IHC, FISH, and real-time PCR analysis of formalin-fixed paraffinembedded tissue. Pathol Lab Med Int 2013; 5: 31-37.
Mohammadizadeh F, Hani M, Ranaee M, Bagheri M. Role of cyclin D1 in breast carcinoma. J Res Med Sci 2013; 18: 1021.
Burandt E, Grünert M, Lebeau A, Choschzick M, Quaas A, Jänicke F, Müller V, Scholz U, Bokemeyer C, Petersen C. Cyclin D1 gene amplification is highly homogeneous in breast cancer. Breast Cancer 2016; 23: 111-119.
Bautista S, Theillet C. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei. Genes Chromosomes Cancer 1998; 22: 268-277.
Van Dang C, Xu J, Chen Y, Olopade O I. MYC and breast cancer. Genes Cancer 2010; 1: 629-240. 24. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
Nair R, Roden D, Teo W, McFarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui M. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene 2014; 33: 3992-4002.
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, LopezGarcia MA, Natrajan R, Marchio C, Iorns E, Mackay A et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70: 2085-2094.